Comparative Pharmacology
Head-to-head clinical analysis: ALESSE versus ESTRADIOL AND NORGESTIMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALESSE versus ESTRADIOL AND NORGESTIMATE.
ALESSE vs ESTRADIOL AND NORGESTIMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Estradiol is an estrogen that binds to estrogen receptors, modulating gene expression and exerting effects on reproductive tissues, bone, and cardiovascular system. Norgestimate is a progestin that acts as a partial agonist at progesterone receptors, suppressing gonadotropin secretion and altering cervical mucus and endometrial lining to prevent pregnancy.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
Estradiol 1 mg and norgestimate 0.18/0.215/0.25 mg orally once daily for the first 28-day cycle, with the norgimate dose titrated: 0.18 mg on days 1–7, 0.215 mg on days 8–14, and 0.25 mg on days 15–21, followed by placebo on days 22–28.
None Documented
None Documented
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Estradiol: terminal half-life ~12-14 hours; Norgestimate: norelgestromin terminal half-life ~28 hours, norgestrel ~25 hours. Clinical context: steady-state achieved within 5-7 days.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Estradiol: primarily renal (50-80% as glucuronide and sulfate conjugates), fecal (10-20%). Norgestimate: metabolites excreted renally (55-65%) and fecally (30-40%).
Category C
Category D/X
Estrogen/Progestin Combination Contraceptive
Estrogen